<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Micronutrient management after bariatric surgery&lt;sup&gt;[1]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Micronutrient management after bariatric surgery<sup>[1]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Micronutrient management after bariatric surgery<sup>[1]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="7" width="14%"></colgroup> <tbody> <tr> <td class="subtitle1">Â </td> <td class="subtitle1">Preoperative prevalence</td> <td class="subtitle1">Postoperative prevalence</td> <td class="subtitle1">Symptoms of deficiency</td> <td class="subtitle1">RDA<sup>[2]</sup></td> <td class="subtitle1">Supplementation</td> <td class="subtitle1">Repletion</td> </tr> <tr> <td>Vitamin A<sup>[1,3]</sup></td> <td>Up to 17%<sup>[3]</sup></td> <td> <p>8 to 11% after RYGB</p> 70% after BPD/DS </td> <td>Early signs: <ul class="decimal_heading"> <li>Night blindness </li> <li>Bitot's spots </li> <li>Hyperkeratinization of skin </li> <li>Loss of taste </li> </ul> <br/> Advanced signs: <ul class="decimal_heading"> <li>Corneal damage </li> <li>Blindness </li> </ul> </td> <td> <p>Men: 900 mcg (3000 IU)</p> Women: 700 mcg (2300 IU) </td> <td> <p>LAGB: 5000 IU daily</p> <p>RYGB or SG: 5000 to 10,000 IU daily</p> BPD/DS: 10,000 IU daily </td> <td> <p>Without corneal changes: 10,000 to 25,000 IU daily orally until clinical improvement (1 to 2 weeks)</p> With corneal changes: 50,000 to 100,000 IU daily IM for 3 days, followed by 50,000 IU daily IM for 2 weeks </td> </tr> <tr> <td>Vitamin D</td> <td>25 to 68%</td> <td>25 to 80%</td> <td>Hypocalcemia, tetany, tingling, cramping, metabolic bone disease, muscle pain</td> <td> <p>General: 600 IU</p> <p>Pregnancy, lactation, or over 71 years of age: 800 IU</p> </td> <td>3000 IU D3 daily from all sources to maintain a 25(OH)D level of &gt;30 ng/mL</td> <td>3000 to 6000 IU of D3 daily (preferred), or 50,000 IU of D2 1 to 3 times per week</td> </tr> <tr> <td>Vitamin E</td> <td>2.2%</td> <td>Uncommon</td> <td>Neuromuscular disorders and hemolysis</td> <td> <p>General: 15 mg (22.4 IU)</p> <p>Lactation: 19 mg (28.4 IU)</p> </td> <td> <p>Adults and adolescents 14 or older: 15 mg (22.4 IU) daily</p> <p>Lactation: 19 mg (28.4 IU) daily </p> </td> <td>90 to 300 mg (100 to 400 IU) daily</td> </tr> <tr> <td>Vitamin K</td> <td>Uncommon</td> <td>Uncommon</td> <td>Impaired coagulation</td> <td>90 to 120 mcg</td> <td> <p>LAGB, RYGB, or SG: 90 to 120 mcg daily</p> <p>BPD/DS: 300 mcg daily </p> </td> <td> <p>Acute malabsorption: 10 mg of parenteral vitamin K </p> <p>Chronic malabsorption: 1 to 2 mg per day orally or 1 to 2 mg per week parenterally </p> </td> </tr> <tr> <td>Vitamin B1 (Thiamine)</td> <td>16 to 29%</td> <td>1 to 49%</td> <td> <p>Numbness, tingling in extremities, gait ataxia, edema, vomiting, confusion</p> Wernicke-Korsakoff syndrome: <ul class="decimal_heading"> <li>Encephalopathy </li> <li>Ataxia </li> <li>Oculomotor dysfunction </li> <li>Confabulation </li> <li>Impaired memory </li> <li>Impaired learning </li> </ul> <br/> Beriberi: <ul class="decimal_heading"> <li>Neuropathy </li> <li>Pain </li> <li>Paresthesia </li> <li>Loss of reflexes </li> </ul> </td> <td>1.5 mg</td> <td> <p>&gt;12 mg daily, preferably 50 to 100 mg daily from a B-complex supplement</p> With IV hydration, 100 mg of thiamine should be added to the solution (should <strong>not</strong> contain glucose if Wernicke encephalopathy is suspected) </td> <td> <p>Oral: 100 mg two to three times daily until symptoms resolve</p> <p>Intravenous: 200 mg three times daily to 500 mg once or twice daily for 3 to 5 days, followed by 250 mg daily for 3 to 5 days, and subsequent oral maintenance (100 mg daily) indefinitely</p> Intramuscular: 250 mg daily for 3 to 5 days, or 100 to 250 mg monthly </td> </tr> <tr> <td>Vitamin B12</td> <td>0 to 18%</td> <td>33% after RYGB; 4 to 20% after SG</td> <td>Macrocytic (megaloblastic) anemia, mild pancytopenia, neuropsychiatric findings (eg, depression, neuropathy)</td> <td>2.4 mcg</td> <td>Oral dose of 350 to 1000 mcg daily, or 1000 mcg IM or SQ monthly, or by nasal spray</td> <td>1000 mcg daily until the level is normalized, then resume maintenance dose</td> </tr> <tr> <td>Folate</td> <td>0 to 54%</td> <td>Up to 65% after RYGB; 18% after SG</td> <td>Macrocytic (megaloblastic) anemia, mild pancytopenia, neural tube defects</td> <td>400 mcg</td> <td> <p>General: 400 to 800 mcg daily from multivitamin</p> <p>Women of childbearing age: 800 to 1000 mcg daily</p> <p>Should <strong>not</strong> exceed 1 mg per day</p> </td> <td>Oral dose of 1000 mcg daily until the level is normalized, then resume maintenance dose</td> </tr> <tr> <td>Iron</td> <td>0 to 58%</td> <td>LAGB 14%, SG &lt;18%, RYGB 20 to 55%, BPD 13 to 62%, DS 8 to 50%</td> <td> <p>Anemia</p> <p>Pica</p> Impaired learning<br/> </td> <td> <p>Men ages 19 and older and women ages 51 and older: 8 mg per day</p> <p>Women between the ages of 19 to 50: 18 mg per day</p> </td> <td> <p>Males, post-menopausal women, and patients without history of anemia: 18 mg of iron from a multivitamin</p> <p>Menstruating women and men or women who have undergone RYGB, SG, or BPD/DS: &gt;45 to 60 mg of elemental iron daily from all sources* </p> </td> <td> <p>Oral: 150 to 300 mg 2 to 3 times a day</p> <p>Parenteral iron for those who do not respond to oral supplementation</p> </td> </tr> <tr> <td>Zinc</td> <td>24 to 28% overall; 9 to 74% seeking BPD/DS</td> <td>70% after BPD/DS, 40% after RYGB, 19% after SG, 34% after LAGB</td> <td>Growth retardation, delayed sexual maturity, impotence, impaired immune function</td> <td> <p>Women: 8 mg</p> <p>Men: 11 mg </p> </td> <td> <p>BPD/DS: 16 to 22 mg (200% RDA)</p> <p>RYGB: 8 to 22 mg (100 to 200% RDA)</p> <p>SG or LAGB: 8 to 11 mg (100% RDA)</p> <p>Maintain a ratio of 8 to 15 mg of zinc per 1 mg of copper </p> </td> <td> <p>Optimal repletion dose unknown</p> Overdose can be associated with toxicity or copper deficiency </td> </tr> <tr> <td>Copper</td> <td>68% in women seeking BPD</td> <td>90% after BPD/DS, 10 to 20% after RYGB</td> <td>Anemia, neutropenia, ataxia</td> <td>900 mcg</td> <td> <p>BPD/DS or RYGB: 2 mg daily (200% RDA)</p> <p>SG or LAGB: 1 mg daily (100% RDA)</p> <p>Maintain a ratio of 8 to 15 mg of zinc per 1 mg of copper</p> </td> <td> <p>Mild-to-moderate deficiency: 3 to 8 mg copper orally until levels normalize</p> Severe deficiency: 2 to 4 mg intravenous copper for 6 days or until symptoms resolve </td> </tr> <tr> <td>Selenium</td> <td>2%</td> <td>14 to 22% after RYGB and BPD/DS</td> <td>Skeletal muscle dysfunction and cardiomyopathy, mood disorder, impaired immune function, macrocytosis</td> <td>55 mcg</td> <td>Unknown but likely higher than 100 mcg/day<sup>[4]</sup></td> <td>2 mcg/kg/day in patients who develop cardiomyopathy<sup>[5]</sup></td> </tr> <tr> <td>Calcium</td> <td>1 to 10%<sup>[6]</sup></td> <td>3.6% after bariatric surgery (1.9% after RYGB, 9.3% after SG, and 10% after BPD/DS)</td> <td>Bone disease, secondary hyperparathyroidism</td> <td>1000 to 1200 mg</td> <td> <p>RYGB, SG, or LAGB: 1200 to 1500 mg daily in divided doses</p> <p>BPD/DS: 1800 to 2400 mg daily in divided doses</p> </td> <td> <p>RYGB, SG, or LAGB: 1200 to 1500 mg daily in divided doses</p> <p>BPD/DS: 1800 to 2400 mg daily in divided doses</p> </td> </tr> </tbody></table></div><div class="graphic_footnotes">RDA: Recommended Daily Allowance; RYGB: Roux-en-Y gastric bypass; BPD/DS: biliopancreatic diversion with duodenal switch; IU: international unit; LAGB: laparoscopic adjustable gastric band; SG: sleeve gastrectomy; IM: intramuscular; IV: intravenous; SQ: subcutaneous.</div><div class="graphic_reference">References: 

<ol>
<li class="">Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: Cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Surg Obes Relat Dis 2020; 16:175.</li>
<li>U.S. Department of Health and Human Services and U.S. Department of Agriculture. 2015â2020 Dietary Guidelines for Americans, 8th Edition, December 2015. Available at: <a href="https://health.gov/our-work/food-nutrition/previous-dietary-guidelines/2015" target="_blank">https://health.gov/our-work/food-nutrition/previous-dietary-guidelines/2015</a> (Accessed on April 7, 2021).</li>
<li>Stein J, Stier C, Raab H, Weiner R. Review article: The nutritional and pharmacological consequences of obesity surgery. Aliment Pharmacol Ther 2014; 40:582.</li>
<li>Institute of Medicine (U.S.). Panel on Dietary Antioxidants and Related Compounds. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids, National Academy Press, Washington DC 2000.</li>
<li>Al-Matary A, Hussain M, Ali J. Selenium: a brief review and a case report of selenium responsive cardiomyopathy. BMC Pediatr 2013; 13:39.</li>
<li>Shah M, Sharma A, Wermers RA, et al. Hypocalcemia after bariatric surgery: Prevalence and associated risk factors. Obes Surg 2017.</li></ol></div><div id="graphicVersion">Graphic 114101 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
